CD4 count at ART initiation (cell/mm3) | P ** | ||||||
---|---|---|---|---|---|---|---|
< 100 | 100 to 200 | > 200 | |||||
Serious morbidity | |||||||
Overall | 10-2 | ||||||
Events, n (Time at risk/100 PY) | 58 | (348) | 49 | (474) | 85 | (850) | |
Incidence/100 PY (95% CI) | 16.7 | (12.4-20.9) | 10.4 | (7.5-13.3) | 10.0 | (7.9-12.1) | |
WHO stage III or IV events | 0.40 | ||||||
Events number (Time at risk/100 PY) | 13 | (391) | 15 | (549) | 21 | (1009) | |
Incidence/100 PY (95% CI) | 3.1 | (1.3-4.8) | 2.7 | (1.4-4.1) | 2.1 | (1.2-3.0) | |
ANRS grade 3 or 4 | 0.60 | ||||||
Events number (Time at risk/100 PY) | 11 | (392) | 10 | (558) | 24 | (1022) | |
Incidence/100 PY (95% CI) | 2.8 | (1.2-4.5) | 1.8 | (0.7-2.9) | 2.4 | (1.4-3.3) | |
Confirmed malaria | 2.10-2 | ||||||
Events number (Time at risk/100 PY) | 6 | (381) | 15 | (529) | 42 | (968) | |
Incidence/100 PY (95% CI) | 1.6 | (0.3-2.8) | 2.8 | (1.4-4.3) | 4.3 | (3.0-5.7) | |
Other events* | 7.10-2 | ||||||
Events number (Time at risk/100 PY) | 13 | (387) | 9 | (562) | 15 | (1060) | |
Incidence/100 PY (95% CI) | 3.4 | (1.5-5.2) | 1.6 | (0.6-2.7) | 1.4 | (0.7-2.1) | |
Death | 10-4 | ||||||
Events number (Time at risk/100 PY) | 26 | (399) | 13 | (575) | 8 | (1100) | |
Incidence/100 PY (95% CI) | 6.5 | (4.0-9.0) | 2.3 | (1.0-3.5) | 0.7 | (0.2-1.2) | |
Lost to follow-up | 10-4 | ||||||
Events number (Time at risk/100 PY) | 40 | (415) | 47 | (596) | 41 | (1138) | |
Incidence/100 PY (95% CI) | 9.6 | (6.7-12.6) | 7.9 | (5.6-10.1) | 3.6 | (2.5-4.7) | |
Attrition | 10-4 | ||||||
Events number (Time at risk/100 PY) | 66 | (412) | 70 | (592) | 49 | (1132) | |
Incidence/100 PY (95% CI) | 16.0 | (12.1-19.9) | 11.8 | (9.1-14.6) | 4.3 | (3.1-5.5) |